Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris
| Autor: | James G. Krueger, Patricia Gilleaudeau, Irma Cardinale, Artemis Khatcherian, Toyoko Kikuchi, Inna Novitskaya, Edmund Lee, Michelle A. Lowes, Knut M. Wittkowski, Francesca Chamian, Shao-Lee Lin, Mary Sullivan-Whalen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Biopsy Recombinant Fusion Proteins T-Lymphocytes CD11c Inflammation Alefacept Biology Antigen Antigens CD T-Lymphocyte Subsets Psoriasis medicine Humans Aged Multidisciplinary medicine.diagnostic_test Dendritic Cells Biological Sciences Middle Aged medicine.disease Immunohistochemistry Monokine Immunology Female medicine.symptom CD8 medicine.drug Protein Binding |
| Popis: | Psoriasis vulgaris, a skin disease that is considered to be the result of a type 1 autoimmune response, provides an opportunity for studying the changes that occur in a target-diseased tissue during innovative immunotherapies. To gain a more comprehensive picture of the response to an approved biological therapy, we studied alfacept, which is a CD2 binding fusion protein. We examined T cells, dendritic cells (DCs), and expression of a number of inflammatory genes. In 22 patients, 55% demonstrated a clear histological remission of the disease, with a 73% reduction in lesional lymphocytes and a 79% decrease in infiltrating CD8+cells. Only histological responders showed marked reductions in the tissue expression of inflammatory genes IFN-γ, signal transducer and activator of transcription 1, monokine induced by IFN-γ, inducible NO synthase, IL-8, and IL-23 subunits. Parallel decreases in CD83+and CD11c+DCs also were measured by immunohistochemistry. Because we observed that alefacept binds primarily to T cells and not DCs, we suggest that T cells are the primary target for therapy, but that DCs and a spectrum of type 1 inflammatory genes are coordinately suppressed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|